BRPI0611964A2 - moduladores de alquilquinolina e alquilquinazolina cinase - Google Patents
moduladores de alquilquinolina e alquilquinazolina cinaseInfo
- Publication number
- BRPI0611964A2 BRPI0611964A2 BRPI0611964-6A BRPI0611964A BRPI0611964A2 BR PI0611964 A2 BRPI0611964 A2 BR PI0611964A2 BR PI0611964 A BRPI0611964 A BR PI0611964A BR PI0611964 A2 BRPI0611964 A2 BR PI0611964A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- kit
- alkylquinazoline
- alkylquinoline
- kinase modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MODULADORES DE ALQUILQUINOLINA E AL QUILQUINAZOLINA CINASE. A invenção está direcionada a compostos de alquilquinolina e alquilquinazolina de Fórmula 1: em que R~ 1~, R~ 2~, R~ 3~, B, Z, G, Q e X são como definidos aqui, o uso de tais compostos como moduladores de proteína tirosina cinase, particularmente inibidores de FLT3 e/ou c-kit e/ou TrkB, o uso de tais compostos para reduzir ou inibir atividade de cinase de FLT3 e/ou c-kit e/ou TrkB em uma célula ou um indivíduo, e o uso de tais compostos para prevenir ou tratar em um indivíduo um distúrbio proliferativo celular e/ou distúrbios relacionadas a FLT3 e/ou c-kit e/ou TrkB. A presente invenção está direcionada à composições farmacêuticas compreendendo os compostos da presente invenção e a métodos para tratar condições tais como cânceres e outros distúrbios proliferativos celulares.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68938405P | 2005-06-10 | 2005-06-10 | |
US73091905P | 2005-10-27 | 2005-10-27 | |
PCT/US2006/022414 WO2006135721A1 (en) | 2005-06-10 | 2006-06-07 | Alkylquinoline and alkylquinazoline kinase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0611964A2 true BRPI0611964A2 (pt) | 2009-01-27 |
Family
ID=37038081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0611964-6A BRPI0611964A2 (pt) | 2005-06-10 | 2006-06-07 | moduladores de alquilquinolina e alquilquinazolina cinase |
Country Status (18)
Country | Link |
---|---|
US (1) | US8071768B2 (pt) |
EP (1) | EP1893598A1 (pt) |
JP (1) | JP2009501135A (pt) |
KR (1) | KR20080028912A (pt) |
AR (1) | AR054386A1 (pt) |
AU (1) | AU2006257945A1 (pt) |
BR (1) | BRPI0611964A2 (pt) |
CA (1) | CA2611242A1 (pt) |
CR (1) | CR9652A (pt) |
EA (1) | EA200800017A1 (pt) |
EC (1) | ECSP077997A (pt) |
GT (1) | GT200600251A (pt) |
IL (1) | IL187692A0 (pt) |
NO (1) | NO20080174L (pt) |
PE (1) | PE20070014A1 (pt) |
TW (1) | TW200716599A (pt) |
UY (1) | UY29588A1 (pt) |
WO (1) | WO2006135721A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7825244B2 (en) * | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US8760507B2 (en) * | 2008-08-05 | 2014-06-24 | Inspectron, Inc. | Light pipe for imaging head of video inspection device |
CA2785284A1 (en) * | 2009-12-25 | 2011-06-30 | Tomoyuki Kamino | Novel aryl urea derivative |
EP2621923B1 (en) | 2010-09-29 | 2017-03-29 | Intervet International B.V. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
LT2922845T (lt) * | 2012-11-20 | 2018-09-10 | Merial, Inc. | Antihelmintiniai junginiai ir kompozicijos ir jų naudojimo būdai |
BR112016008080B1 (pt) * | 2013-10-16 | 2021-02-23 | Fujifilm Corporation | sal de ácido carboxílico ou um sal de ácido mineral, cristal de succinato, cristal de fumarato e composição farmacêutica |
CA2934010A1 (en) * | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
CA2964276A1 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
JP6412471B2 (ja) * | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
TWI731420B (zh) * | 2018-09-27 | 2021-06-21 | 大陸商深圳微芯生物科技股份有限公司 | 具有吲哚胺-2,3-雙加氧酶抑制活性的喹啉衍生物及其製備方法、藥物組合物、聯合用藥物與用途 |
US20220154220A1 (en) * | 2018-12-21 | 2022-05-19 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Small molecules for increasing precise genome editing efficiency |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3517005A (en) * | 1967-10-26 | 1970-06-23 | Pfizer & Co C | Certain 2- and 4-substituted quinazolines |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
JPS5976082A (ja) | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
GB8320958D0 (en) * | 1983-08-03 | 1983-09-07 | Pfizer Ltd | Quinazoline cardiac stimulants |
US5300515A (en) * | 1991-01-31 | 1994-04-05 | Kyorin Pharmaceutical Co., Ltd. | Carbamic acid derivatives and method for preparing the same |
CA2131528C (en) * | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
EP0822788B1 (en) | 1995-04-19 | 2002-09-04 | Schneider (Usa) Inc. | Drug release coated stent |
WO1998014431A1 (fr) * | 1996-10-01 | 1998-04-09 | Kyowa Hakko Kogyo Co., Ltd. | Composes azotes heterocycliques |
WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
DE69718306D1 (de) | 1996-04-12 | 2003-02-13 | Sumitomo Pharma | Piperidinylpyrimidine derivate |
US5948786A (en) * | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
US5866562A (en) * | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
DE19756388A1 (de) * | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
JP4926320B2 (ja) * | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
AU1071301A (en) | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
EP1309567A2 (en) | 2000-08-18 | 2003-05-14 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic compounds |
EP1309569B1 (en) | 2000-08-18 | 2010-10-06 | Millennium Pharmaceuticals, Inc. | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors |
US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
JP2004520299A (ja) | 2000-12-12 | 2004-07-08 | ニューロジェン・コーポレーション | スピロ[イソベンゾフラン−1,4’−ピペリジン]−3−オン類及び3h−スピロイソベンゾフラン−1,4’−ピペリジン類 |
DE10109866A1 (de) | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
WO2002088107A1 (en) | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
AU2002360753B2 (en) | 2001-12-27 | 2008-08-21 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
KR101093345B1 (ko) | 2002-02-01 | 2011-12-14 | 아스트라제네카 아베 | 퀴나졸린 화합물 |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
CN1678586A (zh) | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
WO2004016597A2 (en) | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF |
EP1566379A4 (en) | 2002-10-29 | 2005-11-09 | Kirin Brewery | QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME |
JP2006511616A (ja) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
JP4845736B2 (ja) | 2003-10-14 | 2011-12-28 | アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ | プロテインキナーゼ阻害剤 |
NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
-
2006
- 2006-06-06 US US11/422,349 patent/US8071768B2/en active Active
- 2006-06-07 BR BRPI0611964-6A patent/BRPI0611964A2/pt not_active Application Discontinuation
- 2006-06-07 AU AU2006257945A patent/AU2006257945A1/en not_active Abandoned
- 2006-06-07 JP JP2008515954A patent/JP2009501135A/ja not_active Withdrawn
- 2006-06-07 EA EA200800017A patent/EA200800017A1/ru unknown
- 2006-06-07 PE PE2006000627A patent/PE20070014A1/es not_active Application Discontinuation
- 2006-06-07 CA CA002611242A patent/CA2611242A1/en not_active Abandoned
- 2006-06-07 WO PCT/US2006/022414 patent/WO2006135721A1/en active Application Filing
- 2006-06-07 KR KR1020087000405A patent/KR20080028912A/ko not_active Application Discontinuation
- 2006-06-07 EP EP06772652A patent/EP1893598A1/en not_active Withdrawn
- 2006-06-08 GT GT200600251A patent/GT200600251A/es unknown
- 2006-06-08 UY UY29588A patent/UY29588A1/es unknown
- 2006-06-09 AR ARP060102422A patent/AR054386A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120477A patent/TW200716599A/zh unknown
-
2007
- 2007-11-27 IL IL187692A patent/IL187692A0/en unknown
- 2007-12-10 EC EC2007007997A patent/ECSP077997A/es unknown
-
2008
- 2008-01-09 CR CR9652A patent/CR9652A/es not_active Application Discontinuation
- 2008-01-10 NO NO20080174A patent/NO20080174L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006135721A1 (en) | 2006-12-21 |
NO20080174L (no) | 2008-02-19 |
US8071768B2 (en) | 2011-12-06 |
GT200600251A (es) | 2007-01-12 |
UY29588A1 (es) | 2006-10-02 |
IL187692A0 (en) | 2008-08-07 |
JP2009501135A (ja) | 2009-01-15 |
TW200716599A (en) | 2007-05-01 |
US20060281772A1 (en) | 2006-12-14 |
EA200800017A1 (ru) | 2008-08-29 |
AR054386A1 (es) | 2007-06-20 |
EP1893598A1 (en) | 2008-03-05 |
KR20080028912A (ko) | 2008-04-02 |
AU2006257945A1 (en) | 2006-12-21 |
CR9652A (es) | 2008-09-09 |
ECSP077997A (es) | 2008-01-23 |
CA2611242A1 (en) | 2006-12-21 |
PE20070014A1 (es) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0611964A2 (pt) | moduladores de alquilquinolina e alquilquinazolina cinase | |
UY29591A1 (es) | Aminopirimidinas como moduladores de quinasas | |
UA98297C2 (en) | Triazolopyridazines as tyrosine kinase modulators | |
ECSP077998A (es) | Moduladores de cinasa de aminoquinolina y aminoquinazolina | |
ECSP077991A (es) | Aminopirimidinas como moduladores de cinasa | |
BRPI0920261A8 (pt) | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica | |
BRPI0517921A (pt) | métodos para preparar compostos de indazol | |
BRPI0514537B8 (pt) | compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende | |
ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
ECSP088561A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
NI200700311A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3 | |
BRPI0611673A2 (pt) | modulaÇço sinÉrgica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase | |
BRPI0612000A2 (pt) | modulaÇço sinergÍstica de flt3 cinase usando alquilquinolinas e alquilquinazolinas | |
BR112023000588A8 (pt) | Derivados de piridazinil amino como inibidores de alk5 | |
UY29592A1 (es) | Aminopirimidinas como moduladores de quinasas | |
BR112023000592A2 (pt) | Derivados de pirido oxazina amino como inibidores de alk5 | |
UY29587A1 (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: JOHNSON AND JOHNSON (US) Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V. |
|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |